Immunic, Inc. to Participate in Investor and Scientific Conferences in June
May 30, 2019SAN DIEGO, May 30, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of…Immunic, Inc. to Participate in Upcoming May Conferences
May 9, 2019SAN DIEGO, May 9, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment…Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer
April 29, 2019SAN DIEGO, April 29, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of…Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases
April 12, 2019– Developing Oral Therapies with Best-in-Class Potential – – Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative…Immunic Therapeutics to Present at the Needham Healthcare Conference on April 10
April 2, 2019Planegg-Martinsried, Germany, April 2, 2019 –Immunic AG, a privately held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive…Immunic Therapeutics to Participate in Investor and Medical Conferences in March
February 28, 2019Planegg-Martinsried, Germany, February 28, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced that management will participate in…Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis
February 26, 2019Planegg-Martinsried, Germany, February 26, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced enrollment of the first patient…Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11
February 6, 2019Planegg-Martinsried, Germany, February 6, 2019 – Immunic AG (Immunic), a privately-held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive Officer…Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
January 7, 2019San Diego, CA, USA and Planegg-Martinsried, Germany, January 7, 2019 – Vital Therapies, Inc. (Nasdaq: VTL), and Immunic AG (Immunic), a private clinical-stage biotechnology…
